Relationship of Inflammation and Pulmonary Function to Fungal Translocation in HIV
Launched by UNIVERSITY OF PITTSBURGH · Aug 15, 2022
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating how inflammation and fungal infections affect lung health in people living with HIV. Researchers want to understand how fungi from the gut might be linked to lung problems and inflammation, especially in those with chronic obstructive pulmonary disease (COPD). COPD is a serious lung condition that is common and can be challenging to treat. The study aims to explore the connections between gut health and lung function, which may help develop better treatments for those with both HIV and lung issues.
To participate in this trial, individuals need to be between 18 and 80 years old, be HIV positive, and have been on effective HIV treatment for at least six months. Participants will undergo tests to measure their lung function and may be asked about their health history. It’s important to note that those with certain recent surgeries, specific lung diseases, or other health conditions may not be eligible. By joining this study, participants could contribute to important research that aims to improve understanding and treatment for lung disease in the context of HIV.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 18 to 80
- • HIV positive
- • Virally-suppressed on ART for at least 6 months
- • subjects enrolled in Dr. Morris's HLRC Studies STUDY20020151, STUDY19080258, STUDY19060243, STUDY19070181, STUDY19070181, STUDY19050326 OR subjects being seen at the HIV/PACT clinics.
- Exclusion Criteria:
- • Contraindication to pulmonary function testing (i.e., abdominal or cataract surgery within 3 months, recent myocardial infarction, etc.).
- • individuals with clinical or radiographic evidence of another significant pulmonary diagnosis (e.g. interstitial lung disease, active asthma)
- • inflammatory bowel disease
- • pregnancy
- • use of antibiotics in the prior 2 weeks
- • immunomodulators in the prior 6 months
- • unable to perform any study procedures.
About University Of Pittsburgh
The University of Pittsburgh is a leading research institution known for its commitment to advancing medical science and improving patient care through innovative clinical trials. With a robust infrastructure for research and a multidisciplinary approach, the university fosters collaboration among experts in various fields, facilitating the development of novel therapies and interventions. Its clinical trial programs emphasize ethical standards, patient safety, and the integration of cutting-edge technology, making the University of Pittsburgh a pivotal contributor to the landscape of clinical research and a trusted partner in the pursuit of health advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pittsburgh, Pennsylvania, United States
Patients applied
Trial Officials
Alison J Morris, MD
Principal Investigator
University of Pittsburgh
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials